Question

Which of the following does not specifically target VEGF receptors?

• A. Bevacizumab
• B. Everolimus
• C. Linalidomide
• D. Neuropilin

Hint:

To understand anti-angiogenic targets: - Bevacizumab targets the soluble VEGF ligand. - Sorafenib Sunitinib target the intracellular tyrosine kinase domain of the VEGF Receptor. - Neuropilin is an endogenous transmembrane co-receptor, not an antineoplastic drug.

Answer 1

The Correct Option is D

Concept: Vascular Endothelial Growth Factor (VEGF) signaling is a major pathway that regulates angiogenesis—the formation of new blood vessels from pre-existing ones. This process is essential for tumor growth and metastasis. The pathway involves soluble VEGF ligands binding to transmembrane tyrosine kinase receptors (VEGFR-1, VEGFR-2, VEGFR-3) on endothelial cells. Let us analyze the relationship of each option to the VEGF receptor axis:
• Option (A) Bevacizumab: Bevacizumab is a recombinant humanized monoclonal antibody designed to block angiogenesis. It specifically binds to the soluble VEGF-A ligand, preventing it from interacting with its receptors (VEGFR-1 and VEGFR-2). Because it targets the ligand rather than the receptor itself, it acts as a neutralizing antibody in the VEGF pathway.
• Option (B) Everolimus: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR). By inhibiting mTOR complex 1 (mTORC1), it blocks downstream intracellular translation pathways. This reduces the expression of hypoxia-inducible factor (HIF-1), which indirectly lowers the production of VEGF ligands but does not target VEGF receptors.
• Option (C) Linalidomide (Lenalidomide): Lenalidomide is an immunomodulatory drug (IMiD) that binds to the cereblon E3 ubiquitin ligase complex. It alters protein degradation, leading to anti-angiogenic effects by decreasing the secretion of VEGF and basic fibroblast growth factor (bFGF), rather than directly targeting VEGF receptors.
• Option (D) Neuropilin: Neuropilins (NRP1 and NRP2) are endogenous transmembrane glycoproteins that serve as co-receptors for VEGF ligands alongside standard VEGFRs. Neuropilin-1 physically binds VEGF-A and forms a complex with VEGFR-2, enhancing downstream signaling. In the context of this question, Neuropilin is an endogenous receptor component involved in the pathway, rather than an exogenous therapeutic agent designed to target or block VEGF receptors. Conclusion: While this question features overlapping pathways since several options modify VEGF expression indirectly, Neuropilin is identified as the correct choice in the examination answer key because it is an endogenous co-receptor rather than a specific drug targeting the system.